← Gitlab overview

Gitlab vs Stryker: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Gitlab Inc (GTLB)

Q3 2026
▲2▼2

GitLab Q3: Strong Growth, But Guidance Miss and Job Cuts Weigh

  • Strong revenue growth and raised guidance GitLab's Q1 revenue grew 23% and Q2 grew 21%, with raised guidance and record bookings. Net annual recurring revenue jumped 40%, showing strong demand for its software development platform.

    This is the core positive driver of the quarter, showing accelerating business momentum.

  • New AI and security tools boost enterprise appeal New agentic AI and security tools, like Duo Agent Platform and Secrets Manager, strengthened GitLab's enterprise appeal. The Flex pricing model grew paid consumption from $15M to over $40M, showing early traction.

    These product launches and pricing changes are key new developments that could drive future growth.

  • Workforce cut and country exits raise execution concerns GitLab cut 14% of its workforce and exited 22 countries, raising concerns about execution and future growth. This restructuring may disrupt operations and slow momentum.

    This is a major negative event that could impact investor confidence and future performance.

  • EPS guidance miss triggers sharp stock drop A significant next-quarter EPS guidance miss caused a 16.7% stock drop, showing investors are focused on near-term profitability. Flex also carries a small revenue timing impact.

    This is the most immediate negative price driver, highlighting profitability concerns.

August 2026
▲4

GitLab's AI and security push pays off with record bookings and raised guidance

  • Agentic AI and security updates GitLab launched new agentic AI and enterprise security tools, including a Duo Agent Platform and Secrets Manager. These make the platform more attractive to large, regulated customers, potentially boosting future revenue from big clients.

    This is a new product event that could drive future demand and is not in earlier reports.

  • Strong Q2 earnings and raised guidance GitLab reported 21% revenue growth, beat profit estimates, and raised full-year guidance. Record bookings and a 40% jump in net annual recurring revenue show customers are spending more, which directly boosts investor confidence.

    This is the core new financial event that caused the stock to surge.

  • Analyst upgrades and price target hikes After earnings, several analysts upgraded the stock and raised price targets, citing record retention and early success of the Flex offering. This validates the growth story and can attract more buyers.

    Analyst actions are new and reflect changing market sentiment post-earnings.

  • Flex consumption model gains traction GitLab's new Flex pricing model helped paid consumption run rate jump to over $40 million from $15 million last quarter. Management targets $100 million by year-end, though a small revenue timing impact is expected.

    This is a new operational metric that shows the new pricing model is working, supporting future growth.

Latest
▲4

GitLab's AI and security push pays off with record bookings and raised guidance

  • Agentic AI and security updates GitLab launched new agentic AI and enterprise security tools, including a Duo Agent Platform and Secrets Manager. These make the platform more attractive to large, regulated customers, potentially boosting future revenue from big clients.

    This is a new product event that could drive future demand and is not in earlier reports.

  • Strong Q2 earnings and raised guidance GitLab reported 21% revenue growth, beat profit estimates, and raised full-year guidance. Record bookings and a 40% jump in net annual recurring revenue show customers are spending more, which directly boosts investor confidence.

    This is the core new financial event that caused the stock to surge.

  • Analyst upgrades and price target hikes After earnings, several analysts upgraded the stock and raised price targets, citing record retention and early success of the Flex offering. This validates the growth story and can attract more buyers.

    Analyst actions are new and reflect changing market sentiment post-earnings.

  • Flex consumption model gains traction GitLab's new Flex pricing model helped paid consumption run rate jump to over $40 million from $15 million last quarter. Management targets $100 million by year-end, though a small revenue timing impact is expected.

    This is a new operational metric that shows the new pricing model is working, supporting future growth.

July 2026
▲2▼1

GitLab beats Q1, cuts jobs, launches AI governance tools

  • Q1 revenue up 23%, guidance raised GitLab reported Q1 revenue of $264.2 million, up 23% year over year, beating estimates. It raised full-year revenue guidance to $1.112–$1.118 billion. Strong results and outlook signal healthy demand, supporting the stock price.

    This is the core financial update that directly affects investor expectations for future growth.

  • 14% workforce cut and exit from 22 countries GitLab announced a 14% workforce reduction and exit from 22 countries to cut costs and focus on core priorities. This may boost margins but raises concerns about execution and growth, creating mixed signals for the stock.

    The restructuring is a major strategic shift that impacts both profitability and future growth prospects.

  • EPS guidance miss triggered 16.7% stock drop Despite revenue beat, GitLab's next-quarter EPS guidance missed significantly, causing shares to fall 16.7%. This shows investors focus on near-term profitability, which remains a risk and weighs on the stock.

    The sharp negative market reaction highlights a key investor concern that offsets positive revenue news.

  • GitLab 19.2 adds governed AI automation GitLab launched version 19.2 with agentic AI features that automate code fixes and security reviews, addressing enterprise demand for governed AI. This strengthens its competitive position and could drive future revenue growth.

    New product capabilities are a key driver of long-term demand and competitive differentiation.

▲2▼1

GitLab beats Q1, cuts jobs, launches AI governance tools

  • Q1 revenue up 23%, guidance raised GitLab reported Q1 revenue of $264.2 million, up 23% year over year, beating estimates. It raised full-year revenue guidance to $1.112–$1.118 billion. Strong results and outlook signal healthy demand, supporting the stock price.

    This is the core financial update that directly affects investor expectations for future growth.

  • 14% workforce cut and exit from 22 countries GitLab announced a 14% workforce reduction and exit from 22 countries to cut costs and focus on core priorities. This may boost margins but raises concerns about execution and growth, creating mixed signals for the stock.

    The restructuring is a major strategic shift that impacts both profitability and future growth prospects.

  • EPS guidance miss triggered 16.7% stock drop Despite revenue beat, GitLab's next-quarter EPS guidance missed significantly, causing shares to fall 16.7%. This shows investors focus on near-term profitability, which remains a risk and weighs on the stock.

    The sharp negative market reaction highlights a key investor concern that offsets positive revenue news.

  • GitLab 19.2 adds governed AI automation GitLab launched version 19.2 with agentic AI features that automate code fixes and security reviews, addressing enterprise demand for governed AI. This strengthens its competitive position and could drive future revenue growth.

    New product capabilities are a key driver of long-term demand and competitive differentiation.

Stryker Corporation (SYK)

Q3 2026
▲3▼1

Stryker's strong Q2 beat offset by supply snag and joint replacement weakness

  • Q2 beat and raised guidance Stryker's Q2 sales rose 9.4% to $6.6B and adjusted EPS hit $3.69, beating expectations, prompting management to raise full-year guidance. This shows the core business is healthy and growing faster than expected.

    This is the main positive fundamental driver for the period, showing strong financial performance.

  • Mako robotics milestone and new product launch Mako robotics surpassed 2.5 million procedures, and Stryker launched the Mako RPS handheld knee system. These innovations strengthen Stryker's position in the growing healthcare robotics market and support future demand.

    Highlights technological leadership and new product momentum, key for long-term growth.

  • $100M defense contract and tech partnerships Stryker won a $100M defense contract and advanced acquisitions and Apple Vision Pro technology. This government validation and tech integration open new revenue streams and enhance Stryker's product offerings.

    Shows diversification and external validation, which can boost investor confidence.

  • Manufacturing issue and joint replacement weakness A manufacturing problem limiting inventory and new business is expected to persist into Q4, and joint replacement underperformed on seasonal patterns. These headwinds dragged shares down 7.7% and left SYK down 6.5% YTD.

    This is the main negative force that offset strong fundamentals and pressured the stock price.

August 2026
▲3▼1

Stryker's strong demand and new tech offset by supply and joint replacement setbacks

  • Q2 earnings beat with 9% organic growth and raised outlook Stryker reported 9% organic sales growth, adjusted EPS up 17.9% to $3.69, and margin expansion. Management narrowed full-year organic growth outlook to 8.3-9.3%. This shows the core business is healthy and supports a higher stock price.

    This is the fundamental earnings result that anchors the period's positive momentum.

  • $100 million defense contract modification won Stryker's sales unit won a $100 million contract modification from the US Defense Logistics Agency. This adds incremental revenue and validates its products with a key government customer, giving the stock a short-term boost.

    A concrete new contract that adds demand and supports the stock.

  • Mako robotics surpasses 2.5 million procedures; ZuriMED acquisition and Apple Vision Pro app advance Mako robotics hit 2.5 million procedures globally, showing strong adoption. Stryker also agreed to acquire ZuriMED for rotator cuff technology and completed the first hip arthroscopy using its FDA-cleared Apple Vision Pro app. These moves strengthen its long-term competitive position.

    Highlights innovation and strategic growth that drive future revenue and market share.

  • Supply chain and joint replacement woes drag shares down 7.7% At a healthcare conference, executives said a manufacturing problem continues to limit inventory and new business, now expected to persist into Q4. Joint replacement also underperformed on seasonal patterns. This overshadowed recent gains and pressured the stock.

    This is the major negative event that caused a sharp sell-off and reflects real operational challenges.

Latest
▲3▼1

Stryker's strong demand and new tech offset by supply and joint replacement setbacks

  • Q2 earnings beat with 9% organic growth and raised outlook Stryker reported 9% organic sales growth, adjusted EPS up 17.9% to $3.69, and margin expansion. Management narrowed full-year organic growth outlook to 8.3-9.3%. This shows the core business is healthy and supports a higher stock price.

    This is the fundamental earnings result that anchors the period's positive momentum.

  • $100 million defense contract modification won Stryker's sales unit won a $100 million contract modification from the US Defense Logistics Agency. This adds incremental revenue and validates its products with a key government customer, giving the stock a short-term boost.

    A concrete new contract that adds demand and supports the stock.

  • Mako robotics surpasses 2.5 million procedures; ZuriMED acquisition and Apple Vision Pro app advance Mako robotics hit 2.5 million procedures globally, showing strong adoption. Stryker also agreed to acquire ZuriMED for rotator cuff technology and completed the first hip arthroscopy using its FDA-cleared Apple Vision Pro app. These moves strengthen its long-term competitive position.

    Highlights innovation and strategic growth that drive future revenue and market share.

  • Supply chain and joint replacement woes drag shares down 7.7% At a healthcare conference, executives said a manufacturing problem continues to limit inventory and new business, now expected to persist into Q4. Joint replacement also underperformed on seasonal patterns. This overshadowed recent gains and pressured the stock.

    This is the major negative event that caused a sharp sell-off and reflects real operational challenges.

July 2026
▲3▼1

Stryker's Q2 Beat and Raised Outlook Overshadowed by Post-Earnings Selloff

  • Q2 Beat and Raised 2026 Guidance Stryker reported Q2 sales of $6.6B (up 9.4%) and adjusted EPS of $3.69, beating estimates, and raised its full-year 2026 outlook. This shows the business is recovering strongly from the cyberattack and supports a higher stock price over time.

    This is the core fundamental news that answers why SYK is moving and what drives its value.

  • Shares Drop 6.4% After Earnings Despite Beat Even though results beat expectations, Stryker shares fell 6.4% after the report, leaving the stock down 6.5% year-to-date and at a 23% discount to one fair-value estimate. This shows investors were disappointed by something beyond the headline numbers, creating near-term price pressure.

    This explains the immediate negative price reaction and the current valuation gap, which is central to why the stock is moving now.

  • Mako RPS Handheld Robotic Knee System Launched in U.S. Stryker launched Mako RPS, a handheld robotic knee replacement system, in the U.S. This extends its robotics franchise into a new form factor, potentially broadening adoption and reinforcing the long-term growth story that supports the stock.

    This is a new product catalyst that could drive future demand and investor enthusiasm for SYK.

  • Rotation into High-Quality Healthcare Names Investor Sarat Sethi highlighted a rotation into cash-flow-generating healthcare companies like Stryker, noting the sector's S&P 500 weighting is at an all-time low. This suggests growing investor demand for SYK shares as money moves out of expensive tech.

    This points to a broader market shift that could lift SYK's stock price through increased demand.

▲3▼1

Stryker's Q2 Beat and Raised Outlook Overshadowed by Post-Earnings Selloff

  • Q2 Beat and Raised 2026 Guidance Stryker reported Q2 sales of $6.6B (up 9.4%) and adjusted EPS of $3.69, beating estimates, and raised its full-year 2026 outlook. This shows the business is recovering strongly from the cyberattack and supports a higher stock price over time.

    This is the core fundamental news that answers why SYK is moving and what drives its value.

  • Shares Drop 6.4% After Earnings Despite Beat Even though results beat expectations, Stryker shares fell 6.4% after the report, leaving the stock down 6.5% year-to-date and at a 23% discount to one fair-value estimate. This shows investors were disappointed by something beyond the headline numbers, creating near-term price pressure.

    This explains the immediate negative price reaction and the current valuation gap, which is central to why the stock is moving now.

  • Mako RPS Handheld Robotic Knee System Launched in U.S. Stryker launched Mako RPS, a handheld robotic knee replacement system, in the U.S. This extends its robotics franchise into a new form factor, potentially broadening adoption and reinforcing the long-term growth story that supports the stock.

    This is a new product catalyst that could drive future demand and investor enthusiasm for SYK.

  • Rotation into High-Quality Healthcare Names Investor Sarat Sethi highlighted a rotation into cash-flow-generating healthcare companies like Stryker, noting the sector's S&P 500 weighting is at an all-time low. This suggests growing investor demand for SYK shares as money moves out of expensive tech.

    This points to a broader market shift that could lift SYK's stock price through increased demand.

Q2 2026
▲2▼2

Stryker's Q1 Miss and Cyberattack Hit, but Cash Flow and Robotics Offer Hope

  • Q1 revenue miss and cyberattack disruption Stryker's Q1 revenue of $6.02B missed the $6.33B consensus, and adjusted EPS of $2.60 fell short of $2.98, largely due to a March 11 cyberattack and $118M restructuring charges. The stock has dropped 17.6% over the past year, reflecting investor concern.

    This is the core negative event that explains the recent stock decline and is central to the question.

  • Analyst price target cuts on softer utilization and inflation BofA cut its price target to $380 from $450, and Leerink lowered its target to $407 from $410, both citing softer healthcare utilization, inflation, and reduced margin expansion. These cuts weigh on sentiment and suggest lower future earnings.

    Analyst actions directly influence investor expectations and stock price, and they reflect broader sector headwinds.

  • Strong free cash flow and reiterated guidance Stryker's free cash flow hit 137% of net income, and management reiterated full-year organic growth of 8-9.5%, expecting to recover most cyberattack-related revenue in H2. This cash strength supports the rebound story and long-term investments.

    This positive counterweight shows underlying financial health and management confidence, which could support the stock.

  • Mako robotics positioned in growing healthcare automation trend Healthcare robotics is projected to grow from $14.9B in 2023 to $57B by 2032, driven by aging populations and clinician shortages. Stryker's Mako orthopedic system exemplifies this trend, potentially boosting demand for its procedures and supporting future growth.

    This highlights a long-term growth driver that could offset near-term headwinds and attract investors.

June 2026
▲2▼2

Stryker's Q1 Miss and Cyberattack Hit, but Cash Flow and Robotics Offer Hope

  • Q1 revenue miss and cyberattack disruption Stryker's Q1 revenue of $6.02B missed the $6.33B consensus, and adjusted EPS of $2.60 fell short of $2.98, largely due to a March 11 cyberattack and $118M restructuring charges. The stock has dropped 17.6% over the past year, reflecting investor concern.

    This is the core negative event that explains the recent stock decline and is central to the question.

  • Analyst price target cuts on softer utilization and inflation BofA cut its price target to $380 from $450, and Leerink lowered its target to $407 from $410, both citing softer healthcare utilization, inflation, and reduced margin expansion. These cuts weigh on sentiment and suggest lower future earnings.

    Analyst actions directly influence investor expectations and stock price, and they reflect broader sector headwinds.

  • Strong free cash flow and reiterated guidance Stryker's free cash flow hit 137% of net income, and management reiterated full-year organic growth of 8-9.5%, expecting to recover most cyberattack-related revenue in H2. This cash strength supports the rebound story and long-term investments.

    This positive counterweight shows underlying financial health and management confidence, which could support the stock.

  • Mako robotics positioned in growing healthcare automation trend Healthcare robotics is projected to grow from $14.9B in 2023 to $57B by 2032, driven by aging populations and clinician shortages. Stryker's Mako orthopedic system exemplifies this trend, potentially boosting demand for its procedures and supporting future growth.

    This highlights a long-term growth driver that could offset near-term headwinds and attract investors.

▲2▼2

Stryker's Q1 Miss and Cyberattack Hit, but Cash Flow and Robotics Offer Hope

  • Q1 revenue miss and cyberattack disruption Stryker's Q1 revenue of $6.02B missed the $6.33B consensus, and adjusted EPS of $2.60 fell short of $2.98, largely due to a March 11 cyberattack and $118M restructuring charges. The stock has dropped 17.6% over the past year, reflecting investor concern.

    This is the core negative event that explains the recent stock decline and is central to the question.

  • Analyst price target cuts on softer utilization and inflation BofA cut its price target to $380 from $450, and Leerink lowered its target to $407 from $410, both citing softer healthcare utilization, inflation, and reduced margin expansion. These cuts weigh on sentiment and suggest lower future earnings.

    Analyst actions directly influence investor expectations and stock price, and they reflect broader sector headwinds.

  • Strong free cash flow and reiterated guidance Stryker's free cash flow hit 137% of net income, and management reiterated full-year organic growth of 8-9.5%, expecting to recover most cyberattack-related revenue in H2. This cash strength supports the rebound story and long-term investments.

    This positive counterweight shows underlying financial health and management confidence, which could support the stock.

  • Mako robotics positioned in growing healthcare automation trend Healthcare robotics is projected to grow from $14.9B in 2023 to $57B by 2032, driven by aging populations and clinician shortages. Stryker's Mako orthopedic system exemplifies this trend, potentially boosting demand for its procedures and supporting future growth.

    This highlights a long-term growth driver that could offset near-term headwinds and attract investors.

© 2026 MarketIVWhy